CANF Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2024Q3

150.00K

-23.47%

Estimates Revision

The market is revising No Change the revenue expectations for Can-Fite BioPharma Ltd. (CANF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -63.60%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-63.60%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CANF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is 2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

2025-12-24

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-12-24

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Can-Fite BioPharma to Hold from Buy with no price target after the company's board approved a reverse split of its ordinary shares alongside a corresponding change in the American Depository Share ratio. The firm is lowering its rating ahead of the actual split, consistent with its policy, the analyst noted.

H.C. Wainwright

initiated

$2.50

2025-11-04

Reason

H.C. Wainwright

Price Target

$2.50

2025-11-04

initiated

Reason

H.C. Wainwright assumed coverage of Can-Fite BioPharma with a Buy rating and $2.50 price target. The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-04-15

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-04-15

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-21

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-20

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-20

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$10

2025-03-18

Reason

D. Boral Capital

Jason Kolbert

Price Target

$10

2025-03-18

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is -0.83, compared to its 5-year average forward P/E of -0.74. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.74

Current PE

-0.83

Overvalued PE

4.24

Undervalued PE

-5.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.21

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.81

Undervalued EV/EBITDA

-0.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

24.52

Current PS

243.93

Overvalued PS

67.87

Undervalued PS

-18.82

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CANF News & Events

Events Timeline

No data

News

8.5

2025-12-27Yahoo Finance

UiPath to Join S&P Midcap 400 Index Effective January 2, 2026

2.0

2025-12-26Benzinga

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split, Shares Plunge 38.4%

3.5

2025-12-26NASDAQ.COM

Can-Fite BioPharma Secures Patent in Brazil for A3AR Agonist in Sexual Dysfunction Treatment

People Also Watch

Frequently Asked Questions

What is Can Fite Biopharma Ltd (CANF) stock price today?

The current price of CANF is 4.14 USD — it has decreased -5.05 % in the last trading day.

What is Can Fite Biopharma Ltd (CANF)'s business?

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

What is the price predicton of CANF Stock?

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

Can Fite Biopharma Ltd revenue for the last quarter amounts to 155.00K USD, decreased -21.32 % YoY.

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

Can Fite Biopharma Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for Can Fite Biopharma Ltd (CANF)'s fundamentals?

How many employees does Can Fite Biopharma Ltd (CANF). have?

Can Fite Biopharma Ltd (CANF) has 5 emplpoyees as of January 10 2026.

What is Can Fite Biopharma Ltd (CANF) market cap?

Today CANF has the market capitalization of 3.53M USD.